Valuation: Gilead Sciences, Inc.

Market Cap 181B 155B 145B 133B 249B 17,335B 253B 1,716B 669B 8,708B 680B 666B 28,804B P/E 2026 *
-44.6x
P/E 2027 * 18.2x
Enterprise Value 198B 170B 159B 145B 273B 18,938B 276B 1,874B 731B 9,513B 743B 727B 31,466B EV / Sales 2026 *
6.45x
EV / Sales 2027 * 5.82x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.32%
1 day+1.97%
1 week+5.76%
Current month+12.18%
1 month+12.22%
3 months+11.55%
6 months-4.37%
Current year+16.88%
1 week 28.07
Extreme 28.07
30.01
1 month 25.84
Extreme 25.84
30.01
Current year 23.97
Extreme 23.97
31.8
1 year 22.49
Extreme 22.49
31.8
3 years 20.08
Extreme 20.08
31.8
5 years 20.08
Extreme 20.08
31.8
10 years 20.08
Extreme 20.08
31.8
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+5.76% - - 181B
+0.88%+6.38%+76.86%+128.23% 1,119B
+1.07%+3.80%+51.03%+61.48% 651B
+1.20%+6.21%+26.47%+76.45% 468B
+1.02%+5.77%+43.09%+47.70% 374B
+0.85%+4.07%+23.88%+41.58% 302B
+1.26%+6.81%+1.59%+14.67% 259B
+1.88%+5.81%+48.54%+68.52% 238B
+1.59%+2.09%-15.52%-52.29% 208B
+1.87%+5.61%+25.81%+92.42% 181B
Average +1.36%+4.97%+31.31%+53.20% 422.21B
Weighted average by Cap. +1.18%+5.09%+44.31%+72.55%

Financials

2026 *2027 *
Net sales 30.69B 26.29B 24.6B 22.52B 42.26B 2,937B 42.82B 291B 113B 1,475B 115B 113B 4,879B 32.7B 28.01B 26.21B 23.99B 45.02B 3,128B 45.61B 310B 121B 1,571B 123B 120B 5,198B
Net income -4.27B -3.66B -3.43B -3.14B -5.89B -409B -5.96B -40.48B -15.79B -205B -16.05B -15.7B -680B 10.28B 8.8B 8.24B 7.54B 14.15B 983B 14.33B 97.3B 37.94B 494B 38.58B 37.74B 1,633B
Net Debt 16.75B 14.34B 13.42B 12.29B 23.06B 1,602B 23.36B 159B 61.84B 805B 62.88B 61.51B 2,662B 9.12B 7.82B 7.31B 6.69B 12.56B 873B 12.73B 86.4B 33.7B 439B 34.26B 33.52B 1,451B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-08-21 $29.56 +1.97% 2,030
26-08-20 $28.99 -3.30% 2,248
26-08-19 $29.98 +3.70% 1,313
26-08-18 $28.91 +2.99% 693
26-08-17 $28.07 +0.43% 386
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
146.12USD
Average target price
157.41USD
Spread / Average Target
+7.72%

Quarterly revenue - Rate of surprise